Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05641961 · ClinicalTrials.gov registry record · NA

Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care

A NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05641961: Recruiting NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by University of California, San Francisco.

NCT05641961 is a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05641961, a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies the effectiveness of a newly developed survivorship mobile application (app) designed for survivors, or their caregivers, of childhood cancer to help them better navigate long-term follow-up care. The survivorship app provides survivors access to their treatment history and follow-up recommendations, improves knowledge of their diagnosis, treatment, risks, and recommended follow-up care by using a message notification. The ability to quickly connect and establish care planning may enhance adherence to recommended follow-up.

Primary Outcome

The knowledge of the participant will be measured using a 12-item questionnaire that assesses the awareness of their treatment and health issues in four categories: (1) diagnosis, (2) treatment, (3) risks, and (4) recommended follow-up. A scoring system has been devised which will give a score to each questionnaire out of 100 possible points. The change in participants knowledge scores \>=20 points from baseline will be reported.

Interventions

  • OTHER Questionnaires
  • BEHAVIORAL Survivorship mobile application

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-11-29
Est. Completion 2026-04-30
Phase NA

What NCT05641961 shows while recruiting

NCT05641961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Questionnaires is the first listed.

NCT05641961 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05641961 about?

NCT05641961 is a clinical study titled "Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care". This clinical trial studies the effectiveness of a newly developed survivorship mobile application (app) designed for survivors, or their caregivers, of childhood cancer to help them better navigate long-term follow-up care. The survivorship app provides survivors access to their treatment history a...

What is the current status of trial NCT05641961?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-11-29. Estimated completion is 2026-04-30.

What conditions does trial NCT05641961 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Childhood Cancer.

What interventions are being tested in trial NCT05641961?

The interventions under investigation include: Questionnaires (OTHER), Survivorship mobile application (BEHAVIORAL).

Who is sponsoring clinical trial NCT05641961?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05641961 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05641961's enrollment target sits among peer trials

30 146th of 176 higher than 26 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05641961, the US trial registry maintained by the National Library of Medicine. NCT05641961 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.